197 related articles for article (PubMed ID: 37890146)
1. Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myeloma.
Bae J; Kitayama S; Herbert Z; Daheron L; Kurata K; Keskin DB; Livak K; Li S; Tarannum M; Romee R; Samur M; Munshi NC; Kaneko S; Ritz J; Anderson KC
Blood; 2024 Mar; 143(10):895-911. PubMed ID: 37890146
[TBL] [Abstract][Full Text] [Related]
2. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8
Bae J; Samur M; Richardson P; Munshi NC; Anderson KC
Leukemia; 2019 Sep; 33(9):2208-2226. PubMed ID: 30872779
[TBL] [Abstract][Full Text] [Related]
3. BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8
Bae J; Parayath N; Ma W; Amiji M; Munshi N; Anderson KC
Leukemia; 2020 Jan; 34(1):210-223. PubMed ID: 31427721
[TBL] [Abstract][Full Text] [Related]
4. Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy.
Kawai Y; Kawana-Tachikawa A; Kitayama S; Ueda T; Miki S; Watanabe A; Kaneko S
Mol Ther; 2021 Oct; 29(10):3027-3041. PubMed ID: 34023508
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
[TBL] [Abstract][Full Text] [Related]
6. Sustainable Antiviral Efficacy of Rejuvenated HIV-Specific Cytotoxic T Lymphocytes Generated from Induced Pluripotent Stem Cells.
Miki S; Kawai Y; Nakayama-Hosoya K; Iwabuchi R; Terahara K; Tsunetsugu-Yokota Y; Koga M; Matano T; Kaneko S; Kawana-Tachikawa A
J Virol; 2022 Mar; 96(6):e0221721. PubMed ID: 35107374
[TBL] [Abstract][Full Text] [Related]
7. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
8. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
9. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.
Camviel N; Wolf B; Croce G; Gfeller D; Zoete V; Arber C
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323436
[TBL] [Abstract][Full Text] [Related]
10. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma.
Bilich T; Nelde A; Bauer J; Walz S; Roerden M; Salih HR; Weisel K; Besemer B; Marcu A; Lübke M; Schuhmacher J; Neidert MC; Rammensee HG; Stevanović S; Walz JS
Blood Cancer J; 2020 Feb; 10(2):24. PubMed ID: 32111817
[TBL] [Abstract][Full Text] [Related]
12. T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.
Lucas F; Pennell M; Huang Y; Benson DM; Efebera YA; Chaudhry M; Hughes T; Woyach JA; Byrd JC; Zhang S; Jones D; Guan X; Burd CE; Rosko AE
Biol Blood Marrow Transplant; 2020 Jan; 26(1):7-15. PubMed ID: 31445183
[TBL] [Abstract][Full Text] [Related]
13. γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation.
Chen H; Yu T; Lin L; Xing L; Cho SF; Wen K; Aardalen K; Oka A; Lam J; Daley M; Lu H; Munshi N; Anderson KC; Tai YT
Blood Cancer J; 2022 Aug; 12(8):118. PubMed ID: 35973981
[TBL] [Abstract][Full Text] [Related]
14. Waking up exhausted BCMA-specific T cells in myeloma.
Sacco A; Roccaro AM
Blood; 2024 Mar; 143(10):840-841. PubMed ID: 38451513
[No Abstract] [Full Text] [Related]
15. Directed targeting of B-cell maturation antigen-specific CAR T cells by bioinformatic approaches: From in-silico to in-vitro.
Moazzeni A; Kheirandish M; Khamisipour G; Rahbarizadeh F
Immunobiology; 2023 May; 228(3):152376. PubMed ID: 37058845
[TBL] [Abstract][Full Text] [Related]
16. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
17. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
18. Regeneration of CD8αβ T Cells from T-cell-Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity.
Maeda T; Nagano S; Ichise H; Kataoka K; Yamada D; Ogawa S; Koseki H; Kitawaki T; Kadowaki N; Takaori-Kondo A; Masuda K; Kawamoto H
Cancer Res; 2016 Dec; 76(23):6839-6850. PubMed ID: 27872100
[TBL] [Abstract][Full Text] [Related]
19. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
[TBL] [Abstract][Full Text] [Related]
20. Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy.
Minagawa A; Yoshikawa T; Yasukawa M; Hotta A; Kunitomo M; Iriguchi S; Takiguchi M; Kassai Y; Imai E; Yasui Y; Kawai Y; Zhang R; Uemura Y; Miyoshi H; Nakanishi M; Watanabe A; Hayashi A; Kawana K; Fujii T; Nakatsura T; Kaneko S
Cell Stem Cell; 2018 Dec; 23(6):850-858.e4. PubMed ID: 30449714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]